BioXcel Therapeutics (BTAI) Work In Process (2022 - 2025)

BioXcel Therapeutics (BTAI) posted quarterly Work In Process of $368000.0 for Q4 2025, down 4.91% quarter-over-quarter from $387000.0 in Q2 2024.

BioXcel Therapeutics (BTAI) Work In Process (2022 - 2025) Analysis & Trends

BioXcel Therapeutics' Work In Process history runs 4 years deep, the most recent figure standing at $368000.0 for Q4 2025.

In Q4 2025, Work In Process changed N/A year-over-year to $368000.0; the TTM figure through Dec 2025 stood at $368000.0 (changed N/A YoY), while the FY2025 annual figure was $368000.0, changed N/A from the prior year.
Work In Process for Q4 2025 stood at $368000.0, down from $387000.0 in the prior quarter.
The five-year high for Work In Process was $708000.0 in Q4 2022, with the low at $122000.0 in Q3 2022.
The 4-year median for Work In Process is $395000.0 (2022), against an average of $437125.0.
Peak annual rise in Work In Process reached 395.9% in 2023, while the deepest fall reached 8.05% in 2023.
BioXcel Therapeutics' Work In Process stood at $708000.0 in 2022, then decreased by 8.05% to $651000.0 in 2023, then sank by 40.55% to $387000.0 in 2024, then retreated by 4.91% to $368000.0 in 2025.
Business Quant data shows BTAI's Work In Process at $368000.0 in Q4 2025, $387000.0 in Q2 2024, and $253000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	BioXcel Therapeutics	24.25 Mn	24.25 Mn	160,000.00

Download Data